Payment overview · 2025
General Payments
$270.41
13 reported records · 6 companies
Healthcare provider profile · identity verified
William Dean Rollyson, MD
Allopathic & Osteopathic Physicians|Family Medicine · ELEANOR, WV · NPI 1326625328
Verified facts
What the public records show
CMS Open Payments records show William Dean Rollyson, MD received $270.41 in general payments during 2025 across 13 reported records.
Exact Sciences Corporation accounted for 44.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $118.92 | 44.0% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.04 | 25.9% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $27.46 | 10.2% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $21.02 | 7.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.65 | 6.2% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $16.32 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $270.41 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $97.68 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.69 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.35 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.35 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $27.46 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $16.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 352 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 137 | 70 |
| Lisinopril | Lisinopril | 125 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 113 | 52 |
| Gabapentin | Gabapentin | 110 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 36 |
| Omeprazole | Omeprazole | 79 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 73 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 30 |
| Furosemide | Furosemide | 65 | 35 |
| Losartan Potassium | Losartan Potassium | 63 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 35 |
| Alprazolam | Alprazolam | 58 | 19 |
| Metformin Hcl Er | Metformin Hcl | 56 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 11 |
| Simvastatin | Simvastatin | 55 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Famotidine | Famotidine | 46 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 17 |
| Metformin Hcl | Metformin Hcl | 36 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | 20 |
| Montelukast Sodium | Montelukast Sodium | 33 | 17 |
| Potassium Chloride | Potassium Chloride | 32 | 16 |
| Eliquis | Apixaban | 31 | 17 |
| Tramadol Hcl | Tramadol Hcl | 30 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | 11 |
| Jardiance | Empagliflozin | 25 | 12 |
| Meloxicam | Meloxicam | 25 | 14 |
| Allopurinol | Allopurinol | 24 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | 12 |
| Azelastine Hcl | Azelastine Hcl | 23 | 15 |
| Ozempic | Semaglutide | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 13 |
| Prednisone | Prednisone | 22 | 13 |
| Sertraline Hcl | Sertraline Hcl | 21 | 12 |
| Trazodone Hcl | Trazodone Hcl | 21 | 12 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 11 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | 11 |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $270.41 · 13 records | Exact Sciences Corporation | CHARTIS CATHETER, COLLAGENASE SANTYL, Cologuard Collection Kit, FARXIGA, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY, VIVITROL, VRAYLAR, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error